In summary, dietary FKA is effective in inhibiting urothelial tumorigenesis and increasing the survival of tumor-bearing mice in both UPII-mutant Ha-ras and UPII-SV40T transgenic models, which mimic the papillary pathway (e.g., RAS mutations) and the non-papillary (e.g., TP53 mutation) pathways, respectively, leading to recurrence and progression of human urinary bladder cancer. The gene discussed is TP53; the disease is neoplasm.